This was confirmed in an in vivo model, where the addition of an oncolytic vaccinia virus (GLV‐1h68)12 to the standard ILP protocol, resulted in delayed tumour growth and prolonged survival.9 However, local disease control was not achieved and modifications to this treatment regimen were explored. The gene discussed is XIAP; the disease is neoplasm.